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Available online 2 July 2016Mouse bone marrow stromal stem/progenitor cells (BMSCs, also known as bone marrow-derived mesenchymal
stem cells) and Hematopoietic Stem and Progenitor Cells (HSPCs) with differential proliferative potentials were
investigated for identifying epigenetic signals that can modulate their growth. In the present study,
immunodepletion of granulo-monocytic (CD11b) and erythroid (Ter119) population yielded CD11b−/Ter119−
cells, capable of differentiating into chondrogenic, osteogenic and adipogenic cells. Enrichment of the CD11b+
population by positive selection of multipotent stem/progenitor marker (CD133) yielded CD11b+/CD133+
cells, efﬁciently differentiated into hematopoietic lineages. Molecular characterization revealed the expression
of BMSC and HSPC markers in CD11b−/Ter119− and CD11b+/CD133+ sorted populations, respectively. Cell ex-
pansion studies depicted a higher growth rate and percentage of proliferating cells in G2/M phase of cell cycle in
BMSCs (13.9 ± 2.9%) as compared with HSPCs (5.8 ± 0.8%). Analysis of the HDACs gene expression revealed a
differential expression pattern in BMSCs andHSPCs thatmodulates the cell cycle genes. Trichostatin A (TSA)-me-
diated HDAC inhibition led to an increased level of AcH3 and AcH4 along with cyclins B1 and D2. Chromatin im-
munoprecipitation revealed alleviation of HDAC2 and HDAC3 binding by TSA on cyclins B1 and D2 promoter,
thereby enhancing cell proliferation. This study identiﬁes epigenetic modulation on the proliferative potential
of BMSCs and HSPCs for stem cell transplantation therapies.








Bone marrow stromal stem/progenitor cells (BMSCs, also known as
bone marrow-derived mesenchymal stem cells), possess properties
like self-renewal, multipotency and immuno-modulation that make
them an attractive candidate for cell transplantation therapy.
Friedenstein et al., pioneered the isolation of MSC populations that
were adherent and depicted the self-renewal property (Bianco and
Gehron Robey, 2000). Bone marrow contains heterogeneous cell popu-
lations, including BMSCs, HSPCs, endothelial progenitor cells (EPCs), etc.tem/progenitor cells; HSPCs,
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pen access article under the CC BY-N(Kucia et al., 2005). Studies in the past have used plastic adherence
property to isolate BMSCs from bone marrow (Friedenstein et al.,
1982). However, this technique sufferswith limitations as cells fromhe-
matopoietic origin and various ﬁbroblastic cells often contaminate the
cultures. To date, a number of putative markers have been employed
for isolation of BMSCs (Sacchetti et al., 2007). Among these, CD146+
and STRO-1 expressing cells fromhumanbonemarrow cells (BMSC) ex-
hibited self-renewal capability (Sacchetti et al., 2007). Recently various
studies have been performed to identify murine bone marrow BMSCs
using different cell surface markers including Nestin (Mendez-Ferrer
et al., 2010), leptin receptor (Zhou et al., 2014), and Grem1 (Worthley
et al., 2015) markers. Also studies by Chan et al. identiﬁed postnatal
BMSCs from growth plate of femurs that differentially expressed
markers such as CD45−/Ter-119−/Tie2−/AlphaV+/Thy−/6C3−/
CD105−/CD200+ with capabilities to undergo skeletogenesis (Chan et
al., 2015). BMSCs have also been isolated by immunodepletion of either
CD11b or CD34 or CD45 expressing cells. However isolation with a sin-
gle surfacemarker resulted in contamination of hematopoietic cells (Xu
et al., 2010). Recent studies showed CD34−/low populations are also
comprised of long-term hematopoietic stem cells (HSCs) as well as re-
ports of CD45low expressing BMSC (Donnelly et al., 1999; Osawa et al.,C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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markers for isolation of BMSCs.
HSCs isolated by the set of markers which are Lin−/Sca-1+/C-kit+
(LSK) have been also reported to be heterogeneous (Osawa et al.,
1996). Moreover, Sca-1 expression differs between mouse strains and
therefore is not very effective to enrich HSCs (Spangrude and Brooks,
1993). Likewise, the SLAM family member CD150 is not useful for
emerging and developing HSCs in embryos (McKinney-Freeman et al.,
2009). Other markers such as CD11b/Mac1 is often expressed in the
early HSPCs (Matsubara et al., 2005; Mikkola and Orkin, 2006). The in-
consistencies of surface markers on BMSCs and HSPCs led us to identify
alternative markers with greater speciﬁcity to sort the BMSC and HSPC
populations from bone marrow.
Maintenance of stemness of adult stem cells in their niches is
governed by unique combinations of epigenetic regulators (Oh and
Humphries, 2012). Epigenetic mechanisms, including Histone acetyla-
tion/deacetylation, play a crucial role in transcriptional regulation via
remodelling of chromatin architecture (Huang et al., 2015; Oh and
Humphries, 2012). Histone deacetylases (HDACs), classiﬁed into four
classes, (Gregoretti et al., 2004; Telles and Seto, 2012; Yang and Seto,
2003) catalyzes awide spectrumof physiological process including pro-
liferation, differentiation, apoptosis and cell cycle regulation
(Choudhary et al., 2009).
Mammalian cell cycle progression through four distinct phases, G1/
S/G2/M are mediated via cyclins and cyclin dependent kinases (CDKs)
(Nurse, 1994). These CDKs are successively regulated by Cdk inhibitors
(CKIs) (Sherr and Roberts, 1999). HDACs deacetylate and regulate the
activity of key cell cycle proteins (Glozak et al., 2005). In the past, stud-
ies have been performed to assess the role of HDACs in modulating the
differentiation ability of stem cells, including Embryonic Stem Cells
(ESCs) and adult stem cells (Qiao et al., 2015). However, studies are
lacking in identiﬁcation of HDACs regulation of adult stem cell prolifer-
ation. Often in the event of an injury, adult stem cells migrate from their
niche to regenerate the damaged tissues, which is directly dependent
on its proliferative capacity. Thus, understanding the molecular mecha-
nisms involved during HDAC-mediated cell cycle gene regulation may
provide a better insight into the proliferative potential of these adult
stem/progenitor cells.
In the present study,we have isolated and characterized both BMSCs
and HSPCs from mouse bone marrow based on the presence and ab-
sence of CD11b, Ter119 and CD133 markers. The two resultant sorted
cell populations, CD11b−/Ter119− and CD11b+/CD133+,were success-
fully differentiated into skeletal and hematopoietic lineages, respective-
ly. CDK and CKI gene expression correlated well with the cell cycle
analysis depicting a relatively higher percentage of BMSCs in G2/M
phase, andHSPCs in the G0 phase of the cell cycle. The expression proﬁle
of HDACs in these populations suggests the plausible mechanism of dif-
ferential proliferation. Finally, HDAC inhibition led to an increase in
acetylated Histones and Cyclins B1/D2 levels in these cell populations.
This study suggests the translational role of epigenetic modiﬁers in reg-
ulating the proliferative potential of these adult stem/progenitor cells.
2. Materials and methods
2.1. Isolation and culture of mouse BMSCs and HSPCs
Mouse BMSCs were isolated according to a modiﬁed protocol
(Kopen et al., 1999). Animal experimentation protocols were approved
by the institutional Animal Ethics Committee. Brieﬂy, bonemarrowwas
ﬂushed from the femurs and tibias of 6–8 week old male C57BL6/Jmice,
cells were counted and subjected to immunodepletion of granulo-
monocytic cells using CD11b (Kopen et al., 1999) and Ter119
(Morikawa et al., 2009) antibody coatedmagneticmicrobeads (Miltenyi
Biotech, USA) sequentially in a MACS system according to the
manufacturer's protocol. Similarly, from the CD11b+ cell populations,
selection of HSPCs were achieved using CD133 antibody microbeads(Hess et al., 2006). Two consecutive positive selections yielded
CD11b+/CD133+ bone marrow cells which were separately plated for
subsequent characterization and experiments. Detailed methods of
cell sorting are in the supporting information. Purity check of these
sorted cell populations was achieved using ﬂow cytometry analysis.
2.2. Molecular characterization of BMSCs and HSPCs
Sorted CD11b−/Ter119− and CD11b+/CD133+ cell populations
were characterized for the expression of BMSC- and HSPC- genes and
cell surface proteins, respectively using quantitative Real-time PCR
(qRT-PCR) and ﬂow cytometry approaches. Detailed methodology of
semi-quantitative (Baddoo et al., 2003) and qRT-PCR (Das et al.,
2006), ﬂow cytometric analysis (Baddoo et al., 2003; D'Alessio et al.,
2011), along with cell lineage differentiation assays (Shivdasani and
Schulze, 2005; Zhu et al., 2010) are in the supporting information.
2.3. Growth curve analysis and cell proliferation assays
Sorted cells were seeded at a cell density of 1 × 103 cells per well in
at least triplicates. Cells were harvested at regular intervals of 48 h and
counted microscopically to plot cell growth curves (Pendleton et al.,
2013). Viability of the sorted cell populations were evaluated using
MTT (Geesala et al., 2016) and BrdU (Ploenes et al., 2013) analysis as
discussed in detail in the supporting information.
2.4. Cell cycle analysis
DNA content in the sorted cell populations was also evaluated after
staining with propidium iodide (PI, 0.5 mg/mL, Sigma-Aldrich, USA)
using ﬂow cytometry analysis as described previously (Peng et al.,
2008).
2.4.1. Cell cycle and HDAC gene expression assays
Mouse-speciﬁc forward and reverse primers of cyclins, CKIs, as well
as genes belonging to different classes of HDACs were used for qRT-PCR
analysis to identify their expression levels in the sorted CD11b−/
Ter119− and CD11b+/CD133+ cell populations. All target gene expres-
sion was normalized to eukaryotic 18S rRNA and shown as the – fold
change relative to bone marrow cells as controls (Das et al., 2006).
2.4.2. Colony formation assays
Colony formation efﬁciencies of sorted cells were performed as de-
scribed earlier (Sacchetti et al., 2007). CD11b−/Ter119− cells were cul-
tured in Mesencult medium (StemCell Technologies, Canada) with
different treatments and colonies with 50 or more cells were scored
under inverted microscope. Similarly, CD11b+/CD133+ cells were cul-
tured in Methocult medium and colonies formed were evaluated ac-
cording to standard criteria.
2.4.3. HDAC inhibition by trichostatin A
Sorted CD11b−/Ter119− and CD11b+/CD133+ populations were
treated with increasing concentrations (0, 1, 5 and 10 nM) of
trichostatin A (TSA, Sigma-Aldrich, USA), an HDAC inhibitor, and evalu-
ated for its effect on colony formation assays, growth curve analysis, cell
proliferation using BrdU analysis and cell cycle gene expression analysis
as described previously (Ploenes et al., 2013).
2.4.4. Immunoﬂuorescent staining
Cells were brieﬂy ﬁxed with 4% formaldehyde, permeabilized, and
subjected to methanol ﬁxation overnight. Subsequently, cells were
washed, and either stained with anti-Ki67 rabbit antibody or anti-
BrdU antibody or stained with anti-CD11b, anti-Ter119, anti-Sca-1,
anti-CD29, anti-CD133 antibodies (Biolegends, USA). Detailed steps
are provided in the supporting information.
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Cells treated with or without TSA were lysed, subjected to 10%
SDS–PAGE and transferred onto a polyvinylidene diﬂuoride mem-
brane. Membranes were incubated with primary antibodies
against Cyclins B1, D2, p27, (Cell Signaling Technologies, USA),
HDACs 1, 2, 3 (Abcam, USA) and Acetylated Histones 3 (AcH3)
and 4 (AcH4) (Merck Milipore, USA) at 4 °C for overnight. Detailed
methodology is described in the supporting information (Ploenes
et al., 2013).2.5.1. Chromatin immunoprecipitation (ChIP) assays
ChIP assays were performed as described previously (Kawamura
et al., 2005). Brieﬂy, after ﬁxation of cells with formaldehyde for
cross-linking, cell extracts were sonicated and subsequently
immunoprecipitated separately with mouse anti-HDAC2 or anti-
HDAC3 antibody (Merck Millipore, USA), or with control goat IgG.
Immunocomplexes were pulled down, washed and DNA was isolat-
ed to run qRT-PCR with primers speciﬁc for mouse cyclins B1 and D2
promoter sequences. Detailed steps of the assays are described in
the supporting information.2.6. Statistical analysis
Results represent the mean ± standard error of the mean of at least
three independent experiments, which were performed with a mini-
mum of triplicate samples. Photomicrographs represent typical experi-
ments reproduced at least three times with similar results. Statistical
analyses were performed using a Student's t-test with values of
p b 0.05 considered signiﬁcant.3. Results
3.1. Isolation of mouse BMSCs and HSPCs
Freshly isolated mouse bonemarrow cells were immunodepleted of
granulo-monocytic (CD11b) as well as pro-erythroid (Ter119) cells in
two consecutive rounds of negative selection yielding CD11b−/
Ter119− cell populations (Fig. 1A). Reports have suggested an existence
of CD11b+/low cells in bonemarrow that are capable of self-renewal and
differentiation into hematopoietic lineages. Depletion of these cells
often results in exclusion of important primitive repopulating cells
(Pearce et al., 2004). Thus the CD11b+ cells were further subjected to
a second roundofMACS using amultipotent stem/progenitor cellmark-
er, anti-CD133 (anti-Prominin-1) microbeads yielding CD11b+/
CD133+ sorted cell populations (Fig. 1A). To further establish the purity
of these sorted populations, ﬂow cytometric analysis was performed for
CD11b, Ter119 and CD133 surfacemarkers. CD11b−/Ter119− cellswere
negative for CD11b and Ter119 protein expression (Fig. 1B, upper
panel) while, CD11b+/CD133+ cells were positive for both the surface
proteins (Fig. 1B, lower panel), thus conﬁrming the purity of these
sorted cell populations. Both the sorted CD11b−/Ter119− and
CD11b+/CD133+ cell populations were cultured for 48 h in their pre-
ferred medium and further evaluated for the expression of CD11b,
Ter119 and CD133 using immunoﬂuorescence cytometry. CD11b−/
Ter119− cells depicted an expression of only CD133 but lacked expres-
sion of CD11b and Ter119 whereas CD11b+/CD133+ cells expressed
both CD11b and CD133 (Fig. 1C). CD11b−/Ter119− and CD11b+/
CD133+ cell populations when sub-cultured under optimal expansion
conditions for 7 days depicted strikingly different morphologies. The
phase-contrast microscopic images depict CD11b−/Ter119− cells with
typical ﬁbroblast morphology, whereas CD11b+/CD133+ cells have a
cobble stone appearance (Fig. 1D).3.1.1. Gene expression proﬁle of CD11b−/Ter119− and CD11b+/CD133+
sorted cell populations
We evaluated the expression of BMSC-, HSPC-, pluripotency-speciﬁc
markers along with ligand and cell surface receptor gene expressions in
both sorted populations relative to mouse bone marrow cells using
mouse gene-speciﬁc designed primer setsi as described in Table S1 of
the Supporting information. Further, we compared the gene expres-
sions in these sorted cell populations with bona ﬁde/established
mouse bone marrow-derived BMSCs (Cyagen Biosciences Inc., USA)
and mouse embryonic stem cell line, ES-E14TG2a (ATCC® CRL-1821™,
USA). As shown in Fig. 2A, CD11b−/Ter119− cell populations expressed
approximately 2–3 – fold higher BMSC-related genes such as Nestin,
PodxL, CD73 and CD90.2 than the CD11b+/CD133+ sorted cell popula-
tions. However, CD49f and CD105 (endoglin) expression was compara-
ble between these sorted populations. Expression of Nestin, CD90.2 and
CD105 in CD11b−/Ter119− cells were comparable to mouse BMSCs
(Fig. 2A). Similarly, CD11b+/CD133+ sorted cells expressed 2–8 – fold
higher HSPC-speciﬁc genes such as CD117 (c-Kit), CD14 and Procr1
than CD11b−/Ter119− cell populations (Fig. 2B). The expression of
BMSC-related genes in CD11b+/CD133+ cells and hematopoietic mark-
er genes in CD11b−/Ter119− cells and mouse BMSCs were signiﬁcantly
lower. These gene expression proﬁles suggest the stromal-character of
CD11b−/Ter119− and hematopoietic-character of CD11b+/CD133+
sorted cell populations. Interestingly, expression of pluripotency-specif-
ic genes such as Oct-4, Sox-2 and Nanog was observed to be 4–12 – fold
higher in CD11b−/Ter119− cell populations than CD11b+/CD133+
sorted cells (Fig. 2C). The higher expression patterns of pluripotency-
speciﬁc genes in CD11b−/Ter119− cell populations depicted a similar
high expression in bona ﬁde mouse embryonic stem cell line, ES-
E14TG2a (Fig. 2C). However, the expression of these pluripotency-spe-
ciﬁc genes in ES-E14TG2a, except Sox-2, were several folds higher than
our BMSCs. Expression of SDF-1 was approximately 3.75–fold higher in
CD11b−/Ter119− cell populations than CD11b+/CD133+ sorted cells
(Fig. 2D). However its cognate receptor, CXCR4 aswell as other cell sur-
face receptor expression, VEGFR2, PDGFR-β and TGFRβ -II was equally
expressed in both the freshly sorted cell populations. VEGFR-1 expres-
sion was 6–fold high in CD11b+/CD133+ than CD11b−/Ter119− cell
populations (Fig. 2D). A similar expression proﬁle of these cell surface
receptor genes was observed in bona ﬁdemouse BMSCs and our sorted
CD11b−/Ter119− cell populations (Fig. 2D).
3.2. Surface marker characterization
Next, we performed immuno-phenotype analysis of surface marker
expression in both the sorted cell populations. Flow cytometric analysis
showed that both CD11b−/Ter119− and CD11b+/CD133+ cell popula-
tions were strongly positive for markers like CD29 and CD44. CD49f
along with other markers such as CD106, Sca-1 and CD140a were
expressed differentially by the sorted cell populations (Fig. 3A, B). Inter-
estingly CD11b−/Ter119− cell populations were comparable with bona
ﬁdemouse BMSCs in expression of these surfacemarkers (Fig. S1A). Our
sorted CD11b−/Ter119− cell populations were very low for CD31
whereas CD11b+/CD133+ cell populations were strongly positive for
CD31 (Fig. 3B) suggesting the stromal origin of the former, and
hemangioblast origin, a common precursor of hematopoietic and endo-
thelial cells, of the later sorted cell populations.
3.2.1. Cell lineage-speciﬁc differentiation of CD11b−/Ter119− and CD11b+/
CD133+ sorted cell populations
The potency of these sorted populations was further character-
ized by subjecting to differentiation into various cell lineages. The
CD11b−/Ter119− sorted cell populations were separately subjected
to osteogenic, adipogenic, and chondrogenic induction medium. Dif-
ferentiation of CD11b−/Ter119− sorted cell population into osteo-
genic cells was conﬁrmed by staining with Von Kossa stain to
evaluate the mineralization (calcium) deposits (Fig. S2A), whereas
Fig. 1. Isolation and characterization of CD11b−/Ter119− and CD11b+/CD133+ cells (A) Flow chart of theMACSmethodology adapted for sorting CD11b−/Ter119− and CD11b+/CD133+
cell population. (B) Purity check of theMACS sorted cell populations depicting CD11b−/Ter119− cells were negative for both CD11b and Ter119 expressionwhereas CD11b+/CD133+ cell
population were positive for both CD11b and CD133. (C) Immunocytochemical analysis performed after 48 h of culture depicting the expression of these surface protein markers. (D)
Phase-contrast microscopic images of different sorted populations after culturing for 7 days. Data are representative of more than six independent experiments, sorted and cultured at
different timings.
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alize the fat (oil) droplets formed in the cell (Fig. S2B), and
chondrocytes by staining with toluidine blue for identiﬁcation of
cartilage matrix formation (Fig. S2C). Respective control cells did
not stain for the above three differentiation lineage marker speciﬁc
stains. Quantitation of these images depicted a signiﬁcant increase
in number of positively stained cells (Fig. S2D). These cytological
data was further supported by semi-quantitative RT-PCR analysis
depicting increased expression of osteoblast marker genes, Sparc
(Osteonectin), Bglap2 (Osteocalcin), SPP1 (Osteopontin), Col1α1
and Cbfa1 (RunX2) in CD11b−/Ter119− sorted cells cultured in os-
teogenic induction medium (Fig. S2E). Adipsin, CEBP-α, Lpl and
PPAR-γ expression was markedly high in CD11b−/Ter119− sorted
cells cultured in adipocyte induction medium (Fig. S2F). Similarly,
CD11b−/Ter119− sorted cells cultured in chondrogenic medium
depicted high expression of Col2α1, Col10α1 and Acan (Fig. 4G),
chondrocyte-speciﬁc genes (Fig. S2G). Next, to identify the differen-
tiation potential of CD11b+/CD133+ sorted stem cell populations of
hematopoietic origin, we subjected these cells to colony forming cell
assays for enumerating multipotent hematopoietic stem and
progenitors. Colonies exhibiting burst forming unit-erythroid
(BFU-E), colony forming units –erythroid (CFU-E), –macrophage
(CFU-M), –granulocyte (CFU-G), –granulocyte, –macrophage (CFU-GM) and –granulocyte, erythrocyte, macrophage, megakaryocyte
(CFU-GEMM) appeared after 6–7 days of culture (Fig. S3A).
Separately, CD11b+/CD133+ sorted cell populations cultured in
megakaryocyte-speciﬁc differentiation medium and stained with
Giemsa stain, depicted large cells with lobulated nuclei whereas
control cells retained the undifferentiated hematopoietic morpholo-
gy (Fig. S3B). Quantitation of images revealed a high number of pos-
itively stained cells (Fig. S3C). Also, megakaryocyte-speciﬁc gene
expression (LGALS1, MUC1, Gp9) were observed to be higher as
compared to CD11b+/CD133+ sorted cell populations when cul-
tured in megakaryocyte induction medium (Fig. S3D). 18S rRNA or
β-Actin expression was used as an internal control. Interestingly,
both the sorted cell populations although expressed CD133, an en-
dothelial progenitor marker; however, DiI-AcLDL uptake, a charac-
teristic feature of endothelial cells, was negative (Fig. S4). When
these cells were cultured in EGM-2, they stained positive for DiI-
AcLDL indicating the capability to differentiate into endothelial lin-
eages as reported earlier (Fig. S4) (Janeczek Portalska et al., 2012).
Together, these data suggests that CD11b−/Ter119− sorted cell pop-
ulation of bone marrow are BMSCs with tri-lineage differentiation
capacity, whereas the CD11b+/CD133+ sorted population of bone
marrow are HSPCs, with capability of differentiation into hemato-
poietic lineages.
Fig. 2. Gene expression analysis: Expression of mRNA in these sorted stem cell population was analyzed by evaluating (A) BMSC markers, (B) Hematopoietic Stem Cell markers, (C)
Pluripotency Stem Cell markers and (D) Surface receptor markers. Data depicted are the results of three independent experiments represented as mean ± sem of fold change relative
to bone marrow cells as control (*p b 0.05). Bona ﬁde mouse BMSCs and ESCs were used as positive controls.
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To determine the differences in growth properties of BMSCs and
HSPCs, the growth curve was analyzed in the sorted populations for a
period of 10 days. HSPCs demonstrate a slower growth characteristic
with a doubling time of approximately 142.57 h whereas BMSCs exhib-
ited a relatively higher growth rate with a doubling time of approxi-
mately 93.2 h, based on the logarithmic growth curves (Fig. 4A). Next,
the proliferation rate of these sorted CD11b−/Ter119− and CD11b+/
CD133+ cell populations, evaluated after 48 h using an MTT assay (Fig.
S5A) and BrdU assay (Fig. S5B), depicted lower proliferative potential
with the latter as compared to the former. These observationswere con-
ﬁrmed by immunoﬂuorescence imaging depicting higher BrdU nuclear
staining in CD11b−/Ter119− cells (Fig. S5C) as comparedwith CD11b+/
CD133+ cells (Fig. S5D).3.4. Differential proliferation of BMSCs and HSPCs
To corroborate the expansion characteristics of isolated CD11b−/
Ter119− (BMSCs) and CD11b+/CD133+ (HSPCs), we analyzed the cell
cycle status of these sorted populations. Our results exhibited a signiﬁ-
cant increase in frequency of HSPC populations in G0/G1 phase as com-
pared to BMSCs (89.9 ± 0.6% vs 75.1 ± 3.8%; n = 6; p b 0.004).
Incidentally, a signiﬁcantly higher population of BMSCs were also ob-
served to be in sub-G1 phase (11.46 ± 1.63 vs 4.40 ± 0.56%; n = 6;
p b 0.002). In contrast, BMSCs showed signiﬁcant increase in frequencyof cells in S-G2/M phase than HSPCs (13.9 ± 2.9 vs 5.8 ± 0.8%; n= 6;
p b 0.05) (Fig. 4B). Next, we investigated the expression of cell cycle
control genes in these two sorted populations relative to bone marrow
cells. As shown in Fig. 6C, cyclin B1 and cyclin D2 expression were
5.78- and 2.3-fold higher in BMSCs as compared with HSPCs (cyclin
B1: 2.6 ± 0.93 vs 0.45 ± 0.28; cyclin D2: 2.05 ± 0.95 vs 0.89 ± 0.35),
respectively (Fig. 4C). Furthermore, BMSCs depicted a 3.07–fold higher
expression of cyclin E1 than HSPCs (BMSCs: 4.67 ± 3.1 vs HSPCs:
1.52 ± 0.9) indicating accumulation at the G0/G1 phase (Fig. 4C). The
low proliferative phenotype of HSPCs was further substantiated by a
4.01– and 4.28–fold increase in expression of CDK inhibitors such as
p16 (HSPC: 4.25 ± 0.54 vs BMSC: 1.06 ± 0.16) and p27 (HSPC:
6.37 ± 0.75 vs BMSC: 1.49 ± 0.27), respectively (Fig. 4D). Although
there was an insigniﬁcant differential expression of p21 in these
two sorted populations, the increased expression of both p16 and
p27 in HSPCs suggests that cells are mostly detained in the G0/G1
phase of the cell cycle. Interestingly, p53 expression was very
low in both BMSCs (0.48 ± 0.05) and HSPCs (0.23 ± 0.05), indicat-
ing that cells are not undergoing apoptosis even though there were
fractions of cell populations in both BMSCs and HSPCs in sub-G1
phase of cell cycle (Fig. 4D). BMSCs in comparison with HSPCs
not only depicted 3.04–fold higher expression of proliferating cell
nuclear antigen (PCNA), but also 2– to 4–fold higher gene expres-
sion of E2F transcription factors and cdc20, which are involved in
cell cycle progression and transition from G1 to S phase, indicating
a higher capacity for proliferation of BMSCs in comparison with
isolated HSPCs (Fig. 4E).
Fig. 3. Cell-surface antigen expression analysis: (A) CD11b−/Ter119− sorted cells differentially expressed various cell surface antigens but were very low for CD31 indicating the
mesenchymal origin. (B) CD11b+/CD133+ sorted cell populations were also positive for different cell surface antigens including the hematopoietic markers, CD31. Black histogram on
the extreme left of each row represents negative control (FITC- or PE- labeled IgG1 isotype control). The data reported are the representative of three independent experiments each
performed in duplicates.
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Different classes of HDACs modulate different cell cycle proteins.
BMSCs showed a 5.3– and 7.5–fold increase in HDAC1 and HDAC2 ex-
pression as compared with HSPCs (HDAC1: 9.73 ± 5.49 vs 4.66 ±
2.13; HDAC2: 97.53 ± 40.36 vs 13.02 ± 4.18), thereby suggesting a
HDAC1 and HDAC2–mediated repression of p21 expression, an inhibi-
tor of cyclinD-CDK4/6 complexes (Fig. 5A). This correlates well with
our observation of low expression of p21 and 2–fold higher expression
of cyclin D2 in BMSCs, leading to maintenance of a higher proliferative
state. A decreased p21 expression in our HSPC populations clearly sug-
gests an involvement of other HDACs. Recent studies have shown that
over-expression of HDAC3 in T cells leads to cell cycle arrest and in-
creased p27 expression, an inhibitor of cyclin E-CDK2 and cyclin D-
CDK4 complexes (Hartwell et al., 1970). Similarly, our results depicted
a 2.6–fold increase in expression of HDAC3 in HSPCs as compared
with BMSCs (45.15± 1.16 vs 17.5± 1.44), suggesting an HDAC3-medi-
ated increased expression of p27 rendering these cells into a slow pro-
liferative phenotype (Fig. 5A). Up-regulation of HDAC8 has been
reported to inhibit apoptosis and stimulate cellular proliferation
(Evans et al., 1983). Our results also depicted an increased HDAC8 ex-
pression in BMSCs (25.73 ± 2.51 vs 0.84 ± 0.46), thereby correlating
with the increased cell proliferation phenotype of these cells (Fig. 5A).Further, the role of class II HDACs has been elucidated in proliferation
and differentiation of stem cells (Grana and Reddy, 1995). Among the
various class II type HDACs, HDAC4 and HDAC6 depicted a 4.11– and
2.65–fold higher expression in BMSCs than HSPCs (HDAC4: 48.31 ±
17.4 vs 30.96 ± 14.18; HDAC6: 6.90 ± 3.9 vs 2.55 ± 0.56) (Fig. 5B).
These HDACs primarily function by repressing p21-mediated cell cycle
arrest and up-regulating expression of cyclins-CDK complexes via indi-
rectmechanisms. Similarly, Class III HDACs are also associated in a wide
variety of cellular functions including cellular response to stress, cellular
proliferation and longevity of cells (Michan and Sinclair, 2007). Our
analysis of nuclear Sirtuins (SIRT) -SIRT1, SIRT2, SIRT3, SIRT4, SIRT6
and SIRT7 in BMSCs andHSPCs depicted a 5.5–6–fold increase in expres-
sion of SIRT6 (1.19 ± 0.69 vs 6.46 ± 3.75) and SIRT7 (0.35 ± 0.19 vs
2.12 ± 0.50) in HSPCs suggesting reduced cell proliferation (Fig. 5C).
This ﬁnding is in concurrence with earlier reported over-expression of
SIRT6 in HeLa cells resulting in a low population of cells in mitotic
phase with reduced proliferation rate (Ardestani and Liang, 2012). Fi-
nallyHDAC11 of class IV types of HDAC,whose role is poorly understood
in cell cycle regulation did not depict a marked differential expression
pattern in our sorted BMSC and HSPC populations (Fig. 5D).The differ-
ential expression of HDACs in these cells suggests a probable epigenetic
modiﬁcations in cell proliferation and progression.
Fig. 4. Cell cycle genes expression decides the cell growth status of BMSCs and HSPCs: (A) CD11b−/Ter119− and CD11b+/CD133+ showed differential expansion properties for a period of
10 days. HSPCs depicted a slower growth rate with a doubling period of approximately 142.57 h whereas BMSCs exhibited a relative higher growth rate with doubling period of
approximately 93.2 h, based on the logarithmic growth curves. (B) Flow cytometry analysis of CD11b−/Ter119− and CD11b+/CD133+ sorted cell populations depicting a high peak of
G0/G1 in the latter whereas a relatively high peak of G2/M in the former. Fractions of cell populations of CD11b−/Ter119− and CD11b+/CD133+ sorted cells in different phases of cell
cycle (Inset). qRT-PCR analysis using mouse-gene speciﬁc primer sets depicted differential expression of (C) Cyclin genes, (D) cyclin-dependent kinase inhibitor (CKI) genes and (E)
Cell cycle-associated genes. Data represented are from results of three independent experiments represented as fold change relative to bone marrow cells as control (*p b 0.05).
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HDACderegulation has been revealed in variousmalignancies. How-
ever, their role in adult stem cells is poorly understood. Among the var-
ious HDAC inhibitors, TSA has been reported to possess a higher afﬁnity
to class I HDACs, HDAC1, HDAC2 and HDAC3, and few Class II b HDACs
including HDAC6 and HDAC10 (Bantscheff et al., 2011). TSA treatment
at low nanomolar concentration depicted an increased number of colo-
nies in both the sorted cell populations (Fig. 6A, BMSC (CD11b−/
Ter119−)-upper panel and HSPC (CD11b+/CD133+)-lower panel).
BMSCs (CD11b−/Ter119−) depicted a further marked decrease in dou-
bling period of cell populations in the presence of TSA (5 nM, 48 h) as
comparedwith control (84 h) (Fig. 6B). Similarly, our sorted slowly pro-
liferative HSPC (CD11b+/CD133+) population, when treated with TSA
(5 nM), potentiated the cell growth with a considerable decrease in
doubling time to 33.6 h as compared with control (139.2 h) (Fig. 6C).
These data indicate that overall, the growth rate of both BMSCs and
HSPCs are negatively modulated by HDACs. Next, a dose-dependent in-
crease in cell proliferation was also observed in the presence of TSA
(5 nM), as analyzed using the BrdU incorporation assay, further
conﬁrming the observed cell expansion and growth curve analysis
(Fig. 6D). It was noted that TSA at 5 nM concentration depicted a max-
imum increase in cell proliferation and growth rate in both the analyses
(Fig. 6B, C and D), which corroborates well with the literature (Han et
al., 2013). We further evaluated the effect of TSA in these sorted cell
populations using cell cycle analysis. TSA induced BMSCs (CD11b−/
Ter119−) to exit G0/G1 phase and enter into S phase (33.2 ± 0.6 vs
7.4 ± 1.1) as compared with control (Fig. 6E). Similarly, HSPCs
(CD11b+/CD133+) also exited the G0/G1 phase and entered into the Sphase (18.3 ± 3.4 vs 2.8 ± 1.1) (Fig. 6F). Next, the immunostaining of
these cells depicted a marked increase in Ki67 nuclear staining in TSA
treated group as compared with their respective controls (Fig. 6E and
F). Thus, TSA-mediated inhibition of HDACs induced the cell cycling ca-
pability of these sorted cell populations.
3.4.3. HDAC2 and 3 regulate the cyclins B1 and D2 expression by chromatin
remodelling
Gene expression studies of cyclins revealed a 3.13– and 4.87–fold in-
crease in expression of cyclins B1 and D2mRNA levels in HSPCs treated
with TSA as compared to untreated cell populations. Similarly BMSCs
with a higher growth rate also depicted a signiﬁcant increase in cyclins
B1 andD2mRNAexpression in the presence of TSA (Fig. 7A). At the pro-
tein level, TSA treated cells corroborated withmRNA expression studies
depicting a higher expression of cyclin B1 and cyclin D2 in both BMSCs
and HSPCs (Fig. 7B and C). There was also a marked decrease in p27
mRNA (Fig. 7A) and protein expression in both BMSCs and HSPCs treat-
ed with TSA (Fig. 7D and E) as compared with untreated control cell
populations. These observations suggest a plausible mechanism of
HDAC inhibition-mediated increased cyclins B1 and D2 expression pos-
itively regulates the cell proliferation and growth. TSA treatment of both
BMSCs (CD11b−/Ter119−) and HSPCs (CD11b+/CD133+) depicted a
large increase in acetylated histones H3 and H4 (Fig. 7F, S6A) with a
concomitant decrease in HDAC (HDAC1, HDAC2 and HDAC3) expres-
sion (Fig. 7G, S6B). This further suggests that the hyper-acetylation of
H3 and H4 proteins in the presence of HDAC-inhibition leads to down-
streamactivation of cyclins B1 andD2 in both BMSCs andHSPCs. Finally,
to conﬁrm this phenomenon, ChIP analysis of cyclins B1 and D2 with
Fig. 5. Differential expression of HDACs in CD11b−/Ter119− and CD11b+/CD133+ cell population: HDACs mRNA expression analyzed in these two sorted stem cell population depicted
differential expression of (A) Class I HDACs (B) Class II HDACs (C) Class III HDACs (D) Class IV HDACs. Data depicted are the results of three independent experiments represented as
mean ± sem of fold change relative to bone marrow cells as control (*p b 0.05).
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and 3 binding to cyclins B1 and D2 promoters in the presence of TSA.
The amount of promoter precipitated with anti-HDAC2 and anti-
HDAC3 was signiﬁcantly decreased in both the cell populations treated
with TSA, thereby depicting a decrease in qRT-PCR ampliﬁcation of
cyclins B1 (Fig. 7H) andD2 (Fig. 7I) promoter. This observation suggests
a negative regulation of HDAC2 and HDAC3 on the proliferative pheno-
type of these cells.
4. Discussion
BMSCs and HSPCs are the most intensely studied adult stem cell
types because of their great potential in the ﬁeld of regenerative medi-
cine. Isolation of murine bone marrow derived BMSCs has been per-
formed by immuno-depletion of CD11b cells (Kopen et al., 1999). But,
use of a single marker for isolation of BMSCs often leads to contamina-
tion with other cells of hematopoietic origin which lack CD11b. More-
over, reports of isolation of murine BMSCs using combinatorial
markers have revealed these to be Ter119 negative (Morikawa et al.,
2009). Therefore, in our experimental approach we combined double
negative selection of Ter119, a marker of erythroid cells ranging from
early pro-erythroblasts to mature erythrocytes, along with CD11b for
enrichment of BMSCs. The CD11b−/Ter119− cell population thus ob-
tained appeared morphologically similar to BMSCs in previously pub-
lished literature (Kopen et al., 1999). CD11b+ cell fractions were
earlier reported to contain short termHSPCs.Wehave therefore, furtherenriched HSPCs using CD133 (prominin-1), a stem cell marker known
to be expressed in primitive hematopoietic progenitor cells (Hess et
al., 2006). Studies by Hess et al., demonstrated that CD133+/ALDHhigh/
lin− HSC population signiﬁcantly engrafted in NOD/SCID mice as com-
pared to the CD133− population. Our sorted CD11b+/CD133+ HSPC
populationsdepictedmorphological similaritywith the aforementioned
cell populations (Hess et al., 2006). The expression proﬁle of mRNA and
protein, examined in our sorted cell populations to gauge their biologi-
cal activity, matched with expression proﬁle of markers observed by
Terskikh et al., in puriﬁed HSPCs and committed progenitors (Terskikh
et al., 2003). The pluripotent marker expression on BMSCs has been
studied in detail only in human BMSCs. Riekstina et al., have shown a
differential expression pattern of embryonic stem cell markers includ-
ing Oct-4, Nanog and SOX-2 in stromal cells derived from various
sources such as bone marrow, adipose tissue, dermis and heart
(Riekstina et al., 2009). Similarly, Palma et al. have also shown that
enforced expression of Oct-4 in human BMSCs increases the expression
of other pluripotent genes including KLF-4, SOX-2, FOXD3, NANOG and
c-MYC (Palma et al., 2013). Our studies revealed a similar differential
proﬁle of pluripotency gene expression in murine bone marrow-de-
rived BMSCs and HSPCs; although the levels are generally much lower
than in ES cells.
The sorted BMSC and HSPC populations were observed to exist in
distinct states of the cell cycle, equally important for their functions as
stem cells. The cell cycle gene expression studies further ascertained
the cellular physiology of both the sorted cell populations. Our results
Fig. 6. HDAC inhibition by TSA induces cellular proliferation: HDAC inhibition by TSA leads to increased proliferation in both the CD11b−/Ter119− and CD11b+/CD133+ cell population.
(A) Image depicting increased number of colonies in cells treated with TSA (5 nM) in both the subsets of cells. Growth curve analysis showed an increased cell doubling time after TSA
treatment as compared to control in (B) CD11b−/Ter119− and (C) CD11b+/CD133+ sorted cells. (D) BrdU proliferation assay illustrating a higher percent of proliferative cells in 5 nM
TSA treated cells. Three independent set of experiments were performed and results are depicted as percent proliferation as compared to control (*p b 0.05). (E) CD11b−/Ter119− and
(F) CD11b+/CD133+ cells were separately treated with 5 nM TSA and stained with PI and subjected to cell cycle analysis. TSA treatment increased the cells in S phase (lower panels)
as compared to control (upper panels). The fraction of cells in G0/G1 and S phases of the cell cycle are represented as mean ± sem of three independent experiments.
Immunoﬂuorescence imaging of Ki67 positive cells depicting higher nuclear staining in TSA treated groups.
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cooperate with Hsp-70 to maintain HSPC quiescence (Zou et al., 2011).
Similarly, Passague et al., demonstrated a sequential expression pattern
of cyclins and CKIs during different stages of self-renewal and differen-
tiation in HSPCs (Passegue et al., 2005). The literature suggested that
overexpression of cyclin D2 also led to an increased proliferation in
human BMSCs (Kono et al., 2013). It is pertinent to mention that
although we demonstrated a high percentage of BMSCs expressing
cyclins D2 and B1 in the proliferative phase, the data do not exclude
the existence of a fraction of BMSCs in G0 phase.
In the bonemarrow stemcell niche, variousmolecular cuesmaintain
the physiological states such as proliferation or differentiation of BMSCs
and HSPCs. Emerging evidences suggest that stem cells undergo major
epigenetic alterations during development and differentiation (Huang
et al., 2015). Epigenetic regulation via histone acetylation/deacetylation
is a dynamic process that is orchestrated by the interplay between his-
tone acetyl transferases and HDACs. Studies in the past revealed an im-
portant role of HDACs in stem cell differentiation of both adult and
embryonic stem cells. Small molecule HDAC inhibitors have been
shown to enhance BMSC's differentiation into the adipocyte lineages
by upregulating the expression of PPAR gamma (Yoo et al., 2006). Fur-
ther, in human embryonic stem cells (hESC), TSA has been shown to in-
duce cardiomyocyte differentiation by involving GATA-4 (Kawamura et
al., 2005). Additionally, during neural differentiation, an inhibition of
HDAC activity by TSA promoted pluripotency maintenance at the initial
stage of hESC differentiation, but later inhibited differentiation during
the neural commitment stage (Qiao et al., 2015). HDAC1 and HDAC2deletion in mouse embryonic stem (mESC) cells did not affect ESC pro-
liferation, but led to a marked decrease in ESC differentiation, i.e., em-
bryoid body (EB) formation (Dovey et al., 2010). Further, HDAC1-
deﬁcient EBs were signiﬁcantly smaller, showed spontaneous rhythmic
contraction, and increased expression of both cardiomyocyte and neu-
ronalmarkers (Dovey et al., 2010). Although the role of HDAC inhibition
on stem cell differentiation has been explored extensively, its role on
stem cell proliferation is limited. Wilting et al., have revealed the over-
lapping roles of HDAC1 and HDAC2 in hematopoiesis and cell cycle reg-
ulation by dual inactivation of both HDAC1 and HDAC2, which led to
apoptosis of megakaryocytes and thrombocytopenia (Wilting et al.,
2010). Zupkowitz and colleagues demonstrated the essential require-
ment of HDAC1 for mouse development which is to regulate cellular
proliferation and represses the CKI, p21 (Zupkovitz et al., 2010). In addi-
tion, studies also suggested that loss of HDAC1 in T cells led to increased
proliferation, indicating that the role of HDACs on proliferation is cell
type-dependent. These HDACs are known to regulate different sets of
target genes that govern the outcomeof cellular proliferation in a partic-
ular cell type. Our analysis also revealed a higher expression of both
HDAC1 and HDAC2 in BMSCs as compared with HSPCs, suggesting
their role in regulating the cell cycle. HDAC3, another class I HDAC,
has been shown to control G1-S transition in resting T cells by repressing
Skp2 transcription, leading to increased levels of p27 and consequently
halting the cell cycle in the G0/G1 phase (Zhang et al., 2008). Similarly,
HSPCs expressed a higher level of HDAC3 in our study, which implies
its indirect role in regulating p27-mediated low proliferative state.
Thus, HDACs participate inmaintenance ofwide physiological functions
Fig. 7. TSA-mediated HDAC inhibition differentially regulated histone acetylation, cyclins and CKIs expression: TSA treatment induced acetylation of Histone proteins H3 and H4 and
expression of cyclins at both mRNA and protein level in CD11b−/Ter119− and CD11b+/CD133+ cell population. (A) Graph representing increased mRNA expression of cyclin B1 and
cyclin D2 in TSA treated cells. Three independent set of experiments were performed and results are depicted as difference in mRNA expression in TSA treated group as compared
with respective untreated group (#p b 0.05). Image depicting (B) an increased protein expression of cyclin B1 and cyclin D2, (C) quantitation of band intensities in cyclins B1 and D2,
(D) a decreased protein expression of p27 in TSA treated cells, and (E) densitometric analysis of the observed bands intensities from replicative experiments. Blots depicting (F)
increased acetylation of histones H3 and H4, and (G) decreased protein expression of HDAC1, HDAC2 and HDAC3 in TSA treated cells. ChIP analysis of promoters (H) cyclin B1 and (I)
cyclin D2 using anti-HDAC2 and anti-HDAC3 antibodies. Data representing signiﬁcant differences in TSA treated group as compared with respective untreated group (#p b 0.05).
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molecule inhibitors will provide further insight into themolecular func-
tioning of this highly important class of enzymes.
TSA, a HDAC inhibitor, has a differential afﬁnity to bind various
HDAC complexes (Bantscheff et al., 2011). In the present study, ChIP
analysis revealed thatHDAC2 andHDAC3 are boundwith higher afﬁnity
to the Cyclin B1 promoter in BMSCs and the Cyclin D2 promoter in
HSPCs, which inhibits the expression of these cyclins. However, inhibi-
tion of HDACs with TSA leads to prevention of HDACs from binding to
its target gene promoter, thereby inducing its gene expression. This
phenomenon was evident by a higher pull down of cyclin B1 promoter
by anti-HDAC2 in control cells as comparedwith TSA treated cells. Sim-
ilarly, an increased pull down of cyclin D2 promoter by anti-HDAC3was
observed in control cells as compared with TSA treated cells (graphical
abstract). The present study thus suggests the role of speciﬁc epigenetic
modulators that can induce stem cell growth and expansion.
5. Conclusion
Our study demonstrates use of unique combinations of CD11b,
Ter119 and CD133 markers to isolate enriched BMSCs and HSPCs from
a heterogeneous bone marrow population. The sorted CD11b−/
Ter119− and CD11b+/CD133+cell populationswere successfully differ-
entiated into skeletal and hematopoietic lineages, respectively and con-
ﬁrmed with BMSC and HSPC marker expression. Further, a differential
proliferative potential of these BMSC and HSPC was observed due toexpression of speciﬁc HDACs which acts in concert to express cyclins
and CKIs. Finally, TSA-mediated HDAC inhibition led to decreased bind-
ing of HDAC2and 3 on the cyclins B1 andD2promoters, thereby up-reg-
ulating the expression of these cyclins B1, D2, and subsequent lowering
of the doubling time of these differentially proliferative adult stem cells-
BMSCs and HSPCs.
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